Редактирование: CD2AP

CD2-associated protein (Adapter protein CMS) (Cas ligand with multiple SH3 domains)

==Publications==

{{medline-entry
|title=Recent studies on cellular and molecular mechanisms in Alzheimer's disease: focus on epigenetic factors and histone deacetylase.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/29397389
|abstract=Alzheimer's disease (AD) is one of the most common neurodegenerative disorders mainly affecting elderly people. It is characterized by progressive loss of memory and cognitive function. More than 95% of AD cases are related to sporadic or late-onset AD (LOAD). The etiology of LOAD is still unclear. It has been reported that environmental factors and epigenetic alterations play a significant role in AD pathogenesis. Furthermore, recently, genome-wide association studies (GWAS) identified 10 novel risk genes: [[ABCA7]], [[APOE]], [[BIN1]], [[CD2AP]], [[CD33]], [[CLU]], [[CR1]], [[MS4A6A]], [[MS4A4E]], and [[PICALM]], which play an important role for LOAD. In this review, the therapeutic approaches of AD by epigenetic modifications have been discussed. Nowadays, HDAC inhibitors have clinically proven its activity for epigenetic modifications. Furthermore, we try to establish the relationship between HDAC inhibitors and above mentioned LOAD risk genes. Finally, we are hoping that this review may open new area of research for AD treatment.
|mesh-terms=* Aging
* Alzheimer Disease
* Animals
* Cognition Disorders
* Epigenesis, Genetic
* Genetic Predisposition to Disease
* Genome-Wide Association Study
* Histone Deacetylase Inhibitors
* Histone Deacetylases
* Humans
|keywords=* Alzheimer’s disease
* GWAS
* HDAC inhibitors
* LOAD
* epigenetic modification
|full-text-url=https://sci-hub.do/10.1515/revneuro-2017-0049
}}
{{medline-entry
|title=Association and interaction effects of Alzheimer's disease-associated genes and lifestyle on cognitive aging in older adults in a Taiwanese population.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/28199971
|abstract=Genome-wide association studies and meta-analyses implicated that increased risk of developing Alzheimer's diseases (AD) has been associated with the [[ABCA7]], [[APOE]], [[BIN1]], [[CASS4]], [[CD2AP]], [[CD33]], [[CELF1]], [[CLU]], [[CR1]], [[DSG2]], [[EPHA1]], [[FERMT2]], [[HLA-DRB1]], [[HLA-DRB4]], [[INPP5D]], [[MEF2C]], [[MS4A4A]], [[MS4A4E]], [[MS4A6E]], [[NME8]], [[PICALM]], [[PLD3]], [[PTK2B]], [[RIN3]], [[SLC24A4]], [[SORL1]], and [[ZCWPW1]] genes. In this study, we assessed whether single nucleotide polymorphisms (SNPs) within these 27 AD-associatedgenes are linked with cognitive aging independently and/or through complex interactions in an older Taiwanese population. We also analyzed the interactions between lifestyle and these genes in influencing cognitive aging. A total of 634 Taiwanese subjects aged over 60 years from the Taiwan Biobank were analyzed. Mini-Mental State Examination (MMSE) scores were performed for all subjects to evaluate cognitive functions. Out of the 588 SNPs tested in this study, only the association between [[CASS4]]-rs911159 and cognitive aging persisted significantly (P = 2.2 x 10-5) after Bonferroni correction. Our data also showed a nominal association of cognitive aging with the SNPs in six more key AD-associated genes, including [[EPHA1]]-rs10952552, [[FERMT2]]-rs4901317, [[MEF2C]]-rs9293506, [[PLD3]]-rs11672825, [[RIN3]]-rs1885747, and [[SLC24A4]]-rs67063100 (P = 0.0018~0.0097). Additionally, we found the interactions among [[CASS4]]-rs911159, EPHA-rs10952552, [[FERMT2]]-rs4901317, [[MEF2C]]-rs9293506, or [[SLC24A4]]-rs67063100 on cognitive aging (P = 0.004~0.035). Moreover, our analysis suggested the interactions of [[SLC24A4]]-rs67063100 or [[MEF2C]]-rs9293506 with lifestyle such as alcohol consumption, smoking status, physical activity, or social support on cognitive aging (P = 0.008~0.041). Our study indicates that the AD-associated genes may contribute to the risk of cognitive aging independently as well as through gene-gene and gene-lifestyle interactions.
|mesh-terms=* Age Factors
* Aged
* Alleles
* Alzheimer Disease
* Cognitive Aging
* Epistasis, Genetic
* Female
* Gene-Environment Interaction
* Genetic Association Studies
* Genetic Predisposition to Disease
* Humans
* Life Style
* Male
* Middle Aged
* Polymorphism, Single Nucleotide
* Risk Factors
* Taiwan
|keywords=* Alzheimer’s diseases
* Gerotarget
* Mini-Mental State Examination
* cognitive aging
* gene-gene and gene-lifestyle interactions
* single nucleotide polymorphisms
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421828
}}
{{medline-entry
|title=Gene-based aggregate SNP associations between candidate AD genes and cognitive decline.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/27005436
|abstract=Single nucleotide polymorphisms (SNPs) in and near [[ABCA7]], [[BIN1]], [[CASS4]], [[CD2AP]], [[CD33]], [[CELF1]], [[CLU]], complement receptor 1 ([[CR1]]), [[EPHA1]], [[EXOC3L2]], [[FERMT2]], HLA cluster (DRB5-DQA), [[INPP5D]], [[MEF2C]], MS4A cluster (MS4A3-[[MS4A6E]]), [[NME8]], [[PICALM]], [[PTK2B]], [[SLC24A4]], [[SORL1]], and [[ZCWPW1]] have been associated with Alzheimer's disease (AD) in large meta-analyses. We aimed to determine whether established AD-associated genes are associated with longitudinal cognitive decline by examining aggregate variation across these gene regions. In two single-sex cohorts of older, community-dwelling adults, we examined the association between SNPs in previously implicated gene regions and cognitive decline (age-adjusted person-specific cognitive slopes) using a Sequence Kernel Association Test (SKAT). In regions which showed aggregate significance, we examined the univariate association between individual SNPs in the region and cognitive decline. Only two of the original AD-associated SNPs were significantly associated with cognitive decline in our cohorts. We identified significant aggregate-level associations between cognitive decline and the gene regions [[BIN1]], [[CD33]], [[CELF1]], [[CR1]], HLA cluster, and [[MEF2C]] in the all-female cohort and significant associations with [[ABCA7]], HLA cluster, [[MS4A6E]], [[PICALM]], [[PTK2B]], [[SLC24A4]], and [[SORL1]] in the all-male cohort. We also identified a block of eight correlated SNPs in [[CD33]] and several blocks of correlated SNPs in [[CELF1]] that were significantly associated with cognitive decline in univariate analysis in the all-female cohort. 
|mesh-terms=* Aged
* Aging
* Alzheimer Disease
* Cognition Disorders
* DNA
* Female
* Genetic Association Studies
* Genetic Predisposition to Disease
* Humans
* Male
* Polymorphism, Single Nucleotide
|keywords=* Candidate AD genes
* Cognitive decline
* SNP associations
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005889
}}
{{medline-entry
|title=HYDRA: Revealing heterogeneity of imaging and genetic patterns through a multiple max-margin discriminative analysis framework.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/26923371
|abstract=Multivariate pattern analysis techniques have been increasingly used over the past decade to derive highly sensitive and specific biomarkers of diseases on an individual basis. The driving assumption behind the vast majority of the existing methodologies is that a single imaging pattern can distinguish between healthy and diseased populations, or between two subgroups of patients (e.g., progressors vs. non-progressors). This assumption effectively ignores the ample evidence for the heterogeneous nature of brain diseases. Neurodegenerative, neuropsychiatric and neurodevelopmental disorders are largely characterized by high clinical heterogeneity, which likely stems in part from underlying neuroanatomical heterogeneity of various pathologies. Detecting and characterizing heterogeneity may deepen our understanding of disease mechanisms and lead to patient-specific treatments. However, few approaches tackle disease subtype discovery in a principled machine learning framework. To address this challenge, we present a novel non-linear learning algorithm for simultaneous binary classification and subtype identification, termed HYDRA (Heterogeneity through Discriminative Analysis). Neuroanatomical subtypes are effectively captured by multiple linear hyperplanes, which form a convex polytope that separates two groups (e.g., healthy controls from pathologic samples); each face of this polytope effectively defines a disease subtype. We validated HYDRA on simulated and clinical data. In the latter case, we applied the proposed method independently to the imaging and genetic datasets of the Alzheimer's Disease Neuroimaging Initiative (ADNI 1) study. The imaging dataset consisted of T1-weighted volumetric magnetic resonance images of 123 AD patients and 177 controls. The genetic dataset consisted of single nucleotide polymorphism information of 103 AD patients and 139 controls. We identified 3 reproducible subtypes of atrophy in AD relative to controls: (1) diffuse and extensive atrophy, (2) precuneus and extensive temporal lobe atrophy, as well some prefrontal atrophy, (3) atrophy pattern very much confined to the hippocampus and the medial temporal lobe. The genetics dataset yielded two subtypes of AD characterized mainly by the presence/absence of the apolipoprotein E (APOE) ε4 genotype, but also involving differential presence of risk alleles of [[CD2AP]], [[SPON1]] and LOC39095 SNPs that were associated with differences in the respective patterns of brain atrophy, especially in the precuneus. The results demonstrate the potential of the proposed approach to map disease heterogeneity in neuroimaging and genetic studies.
|mesh-terms=* Aged
* Aged, 80 and over
* Alzheimer Disease
* Atrophy
* Brain
* Cluster Analysis
* Female
* Humans
* Magnetic Resonance Imaging
* Male
* Pattern Recognition, Automated
* Support Vector Machine
|keywords=* ADNI
* Aging
* Alzheimer's disease
* Clustering
* Convex polytope
* Genetics
* Heterogeneity
* MRI
* Max-margin classification
* Multivariate
* Neuroimaging
* SVM
* Semi-supervised pattern analysis
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408358
}}
{{medline-entry
|title=Dendrin ablation prolongs life span by delaying kidney failure.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/26073036
|abstract=Podocyte loss is central to the progression of proteinuric kidney diseases leading to end-stage kidney disease (ESKD), requiring renal replacement therapy, such as dialysis. Despite modern tools and techniques, the 5-year mortality of some patients requiring dialysis remains at about 70% to 80%. Thus, there is a great unmet need for podocyte-specific treatments aimed at preventing podocyte loss and the ensuing development of ESKD. Here, we show that ablation of the podocyte death-promoting protein dendrin delays the onset of ESKD, thereby expanding the life span of mice lacking the adapter protein [[CD2AP]]. Ablation of dendrin delays onset and severity of proteinuria and podocyte loss. In addition, dendrin ablation ameliorates mesangial volume expansion and up-regulation of mesangial fibronectin expression, which is mediated by a podocyte-secreted factor. In conclusion, onset of ESKD and death can be markedly delayed by blocking the function of dendrin. 
|mesh-terms=* Animals
* Disease Progression
* Fibroblasts
* Kidney Diseases
* Kidney Failure, Chronic
* Longevity
* Mice
* Mice, Knockout
* Nerve Tissue Proteins
* Podocytes
* Proteinuria

|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530132
}}
{{medline-entry
|title=Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS).
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/22445811
|abstract=Genetics plays a crucial role in human aging with up to 30% of those living to the mid-80s being determined by genetic variation. Survival to older ages likely entails an even greater genetic contribution. There is increasing evidence that genes implicated in age-related diseases, such as cancer and neuronal disease, play a role in affecting human life span. We have selected the 10 most promising late-onset Alzheimer's disease (LOAD) susceptibility genes identified through several recent large genome-wide association studies (GWAS). These 10 LOAD genes ([[APOE]], [[CLU]], [[PICALM]], [[CR1]], [[BIN1]], [[ABCA7]], [[MS4A6A]], [[CD33]], [[CD2AP]], and EPHA1) have been tested for association with human aging in our dataset (1385 samples with documented age at death [AAD], age range: 58-108 years; mean age at death: 80.2) using the most significant single nucleotide polymorphisms (SNPs) found in the previous studies. Apart from the [[APOE]] locus (rs2075650) which showed compelling evidence of association with risk on human life span (p = 5.27 × 10(-4)), none of the other LOAD gene loci demonstrated significant evidence of association. In addition to examining the known LOAD genes, we carried out analyses using age at death as a quantitative trait. No genome-wide significant SNPs were discovered. Increasing sample size and statistical power will be imperative to detect genuine aging-associated variants in the future. In this report, we also discuss issues relating to the analysis of genome-wide association studies data from different centers and the bioinformatic approach required to distinguish spurious genome-wide significant signals from real SNP associations.
|mesh-terms=* Age Distribution
* Aging
* Alzheimer Disease
* Chromosome Mapping
* Genetic Markers
* Genetic Predisposition to Disease
* Genetic Variation
* Genome-Wide Association Study
* Humans
* Polymorphism, Single Nucleotide
* Prevalence

|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120742
}}
{{medline-entry
|title=Podocyte-specific overexpression of GLUT1 surprisingly reduces mesangial matrix expansion in diabetic nephropathy in mice.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/20375116
|abstract=Increased expression of the facilitative glucose transporter, GLUT1, leads to glomerulopathy that resembles diabetic nephropathy, whereas prevention of enhanced GLUT1 expression retards nephropathy. While many of the GLUT1-mediated effects are likely due to mesangial cell effects, we hypothesized that increased GLUT1 expression in podocytes also contributes to the progression of diabetic nephropathy. Therefore, we generated two podocyte-specific GLUT1 transgenic mouse lines (driven by a podocin promoter) on a db/m C57BLKS background. Progeny of the two founders were used to generate diabetic db/db and control db/m littermate mice. Immunoblots of glomerular lysates showed that transgenic mice had a 3.5-fold (line 1) and 2.1-fold (line 2) increase in GLUT1 content compared with wild-type mice. Both lines showed similar increases in fasting blood glucose and body weights at 24 wk of age compared with wild-type mice. Mesangial index (percent PAS-positive material in the mesangial tuft) increased 88% (line 1) and 75% (line 2) in the wild-type diabetic mice but only 48% (line 1) and 39% (line 2) in the diabetic transgenic mice (P < 0.05, transgenic vs. wild-type mice). This reduction in mesangial expansion was accompanied by a reduction in fibronectin accumulation, and vascular endothelial growth factor (VEGF) levels increased only half as much in the transgenic diabetic mice as in wild-type diabetic mice. Levels of nephrin, neph1, [[CD2AP]], podocin, and GLUT4 were not significantly different in transgenic compared with wild-type mice. Taken together, increased podocyte GLUT1 expression in diabetic mice does not contribute to early diabetic nephropathy; surprisingly, it protects against mesangial expansion and fibronectin accumulation possibly by blunting podocyte VEGF increases.
|mesh-terms=* Adaptor Proteins, Signal Transducing
* Aging
* Albuminuria
* Animals
* Blood Glucose
* Body Weight
* Cytoskeletal Proteins
* Diabetic Nephropathies
* Disease Models, Animal
* Down-Regulation
* Fasting
* Fibronectins
* Glomerular Mesangium
* Glucose Transporter Type 1
* Glucose Transporter Type 4
* Intracellular Signaling Peptides and Proteins
* Membrane Proteins
* Mice
* Mice, Inbred C57BL
* Mice, Transgenic
* Podocytes
* Promoter Regions, Genetic
* Rats
* Up-Regulation
* Vascular Endothelial Growth Factor A

|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904178
}}
{{medline-entry
|title=[[CD2AP]] is expressed with nephrin in developing podocytes and is found widely in mature kidney and elsewhere.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/10997929
|abstract=CD2-associated protein ([[CD2AP]]) is an adapter molecule that can bind to the cytoplasmic domain of nephrin, a component of the glomerular slit diaphragm. Mice lacking [[CD2AP]] exhibit a congenital nephrotic syndrome characterized by extensive foot process effacement, suggesting that [[CD2AP]]-nephrin interactions are critical to maintaining slit diaphragm function. We have examined the patterns of expression of both [[CD2AP]] and nephrin in developing mouse and human kidney. Both proteins were first detected in developing podocytes at the capillary loop stage of glomerulogenesis and eventually became concentrated near the glomerular basement membrane. [[CD2AP]] was also observed diffusely in collecting duct and apically in many cells of proximal and distal tubule. Kidneys from Cd2ap -/- mice initially exhibited normal nephrin localization, but as the mice aged and foot processes became effaced, nephrin disappeared. In laminin-beta(2) mutant mice exhibiting nephrotic syndrome, [[CD2AP]] in glomeruli was aberrantly localized in a primarily punctate pattern. Extensive extrarenal expression of [[CD2AP]] was observed in endothelial and epithelial cells, in many cases with a specific subcellular localization. Together, these results suggest that [[CD2AP]] is not only involved in maintaining the slit diaphragm but may also have a general role in maintaining specialized subcellular architecture. The severity of kidney disease in Cd2ap mutant mice may have eclipsed manifestation of defects in other tissues.
|mesh-terms=* Adaptor Proteins, Signal Transducing
* Aging
* Animals
* Cytoskeletal Proteins
* Embryonic and Fetal Development
* Fetus
* Humans
* Kidney
* Kidney Glomerulus
* Laminin
* Membrane Proteins
* Mice
* Mutation
* Proteins
* Tissue Distribution

|full-text-url=https://sci-hub.do/10.1152/ajprenal.2000.279.4.F785
}}